Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Shareholders Reject Novartis Offer As Inadequate

This article was originally published in The Gray Sheet

Executive Summary

When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52% stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23%, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders.
Advertisement

Related Content

As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
Alcon To Launch LenSx Cataract Surgery Laser In Q4 Following Acquisition
Alcon To Launch LenSx Cataract Surgery Laser In Q4 Following Acquisition
Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover
Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover
Venture Eyes Ophthalmology--And Likes What It Sees
Novartis Sets $39 Billion Path To Purchasing Eye Care Market Leader Alcon
Novartis' New Kind of Pharma Deal
Novartis' New Kind of Pharma Deal

Topics

Advertisement
UsernamePublicRestriction

Register

MT028393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel